The patent medicine market's growth is expected to be hampered by the high cost of patent medicine in comparison to generic medicine. When compared to branded drug manufacturers, generic medicine manufacturing companies incur lower development costs. Furthermore, the majority of pharmaceutical companies practise 'Patent Ever-greening,' which means they try to increase revenue/profit by making minor changes to existing products using the same base formula but different chemical structure formula and securing a patent on it, claiming it novel. Furthermore, due to the high cost of patented medicines, patients in developing countries cannot afford them. These factors are expected to limit the growth of the global patent medicine market over the forecast period.
Read More:
https://knackersblogger.blogspot.com/2022/08/patent-medicine-market-global-industry.html
